E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents

Cancer Research

Volumn 60, Issue 14, 2000, Pages 3957-3964

  Stiewe, T ^a   Parssanedjad, K ^a   Esche, H ^a   Opalka, B ^a   Putzer B M ^a  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CASPASE INHIBITOR; DAUNORUBICIN; ETOPOSIDE; PROTEIN KINASE; VIRUS PROTEIN;

APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL DEATH; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CROSS RESISTANCE; DNA DAMAGE; ENZYME ACTIVITY; ENZYME INACTIVATION; GENOTOXICITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOSIS INHIBITION; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ADENOVIRUS E1A PROTEINS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CASPASES; CDC2 PROTEIN KINASE; CELL CYCLE; CELL DIVISION; DAUNORUBICIN; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; HUMANS; K562 CELLS; LEUKEMIA; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; LUCIFERASES; MICROSCOPY, PHASE-CONTRAST; NUCLEIC ACID SYNTHESIS INHIBITORS; PEPTIDES; PLASMIDS; POLY(ADP-RIBOSE) POLYMERASES; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0034660865     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Chronic myelogenous leukemia: Recent advances
2. Leukemia and the disruption of normal hematopoiesis
3. BCR-Able-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein
4. Phosphatidylinositol-3 kinase activity is regulated by BCR-ABL and is required for the growth of Philadelphia chromosome-positive cells
5. Chronic myelogenous leukemia-new concepts
6. Biology of chronic myelogenous leukemia: Is discordant maturation the primary effect
7. Bcr-Abl. An anti-apoptosis gene in chronic myelogenous leukemia
8. Apoptosis - The story so far
9. Bcr-abl maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death
10. ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block
11. Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells
12. Bcr-abl activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner
13. Regulation of the Fas apoptotic cell death pathway by abl
14. Inhibition of apoptosis by bcr-abl in chronic myeloid leukemia
15. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of bcr-abl tyrosine kinase, CGP 57148
16. Fas-mediated modulation of bcr-abl in chronic myelogenous leukemia results in differential effects on apoptosis
17. Apoptosis. Its significance in cancer and cancer therapy
18. Bcl-xL overexpression inhibits Taxol-induced Yama protease activity and apoptosis
19. BCR-ABL delays apoptosis upstream of procaspase-3 activation
20. Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis
21. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and activation of caspase-3
22. Role of bcr-abl kinase in resistance to apoptosis
23. Functional aspects of apoptosis in hematopoiesis and consequences of failure
24. Two regions of the adenovirus early region 1A proteins are required for transformation
25. The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19.kDa and Bc1-2 proteins
26. Control of p53-dependent apoptosis by E1B, Bcl-2. Ha-ras proteins
27. E2F1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction
28. Deregulated E2F-1 expression leads to S-phase entry and p53-mediated apoptosis
29. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo
30. Regulation of apoptosis by the transforming genes of the DNA tumor virus adenovirus
31. Stabilization of the p53 tumor suppressor is induced by adenovirus-5 E1A and accompanies apoptosis
32. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B
33. Adenovirus E1A proteins induce apoptosis by both p53-dependent and p53-independent mechanisms
34. Accumulation of p53 induced by the adenovirus E1A protein requires regions involved in the stimulation of DNA synthesis
35. Adenovirus type 5 early region 4 is responsible for E1A-induced p53-independent apoptosis
36. The early region 4 orf4 protein of human adenovirus type 5 induces p53-independent cell death by apoptosis
37. E1A is sufficient by itself to induce apoptosis independent of p53 and other adenoviral gene products
38. Lack of correlation between p53 protein level and sensitivity to DNA-damaging agents in keratinocytes carrying adenovirus E1A mutants
39. Adenovirus E1A expression enhances the sensitivity of an ovarian cancer cell line to multiple cytotoxic agents trough an apoptotic mechanism
40. Antibody recognition of the tumor-specific bcr-abl joining region in chronic myeloid leukemia
41. Electroporation intracellular buffer increases cell survival
42. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A
43. Use of a membrane-localized green fluorescent protein allows simultaneous identification of transfected cells and cell cycle analysis by flow cytometry
44. Adenovirus 5 E1A-mediated tumor suppressor associated with E1A-mediated apoptosis in vivo
45. Specific loss of apoptotic but not cell cycle arrest function in a human tumour derived p53 mutant
46. p53 in chronic myelogenous leukemia
47. Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line
48. Apopain/CPP32 cleaves protein that are essential for cellular repair: A fundamental principle of apoptotic death
49. DFF a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis
50. The role of the caspase family of cysteine proteases in apoptosis
51. Induction of apoptosis (programmed cell death) in human leukemic HL-60 cells by inhibition of RNA and protein synthesis
52. Bcr-Abl-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents
53. Herbimycin A accelerates the induction of apoptosis following etoposide treatment or γ-irradiation of bcr/abl-positive leukaemia cells
54. Inhibition of p34cdc2 kinase activity by etoposide or irradiation as a mechanism of G2 arrest in Chinese hamster ovary cells
55. E1A induces phosphorylation of the retinoblastoma protein independently of direct physical association between the E1A and retinoblastoma products
56. Transactivation of the human cdc2 promoter by adenovirus E1A
57. Deregulation of cdc2 gene expression correlates with overexpression of a 110 kDa CCAAT box binding factor in transformed cells
58. Transactivation of the human cdc2 promoter by adenovirus E1A in cycling cells is mediated by the induction of a 110-kDa CCAAT-box-binding factor
59. Complementation of the mitotic activator, p80cdc25, by a human protein-tyrosine phosphatase
60. Antioncogenic effect of adenovirus E1A in human tumor cells
61. Inhibition of intratracheal lung cancer development by systemic delivery of E1A
62. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer
63. Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene
64. L inhibits Ara-C-induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis
65. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors
66. Bcl-2 and adenovirus 19KDA protein prevent E1A-induced processing of CPP32 and cleavage of poly(ADP-ribose) polymerase
67. E4orf4, a novel adenovirus death factor that induces p53-independent apoptosis by a pathway that is not inhibited by zVAD-fmk
68. Evidence that the G1-S G2-M transitions are controlled by different cdc 2 proteins in higher eukaryotes
69. Rescue from granzyme B-induced apoptosis by Weel kinase
70. Premature p34cdc2 activation required for apoptosis
71. Caspase-dependent activation of cyclin-dependent kinases during Fas-induced apoptosis in Jurkat cells
72. Induction of apoptosis by adenovirus type 5 E1A in rat cells requires a proliferation block
73. E1A signaling to p53 involves the p19ARF tumor suppressor
74. p14ARF links the tumor suppressors RB and p53
75. Degradation of topoisomerase IIα during adenovirus E1A-induced apoptosis is mediated by the activation of the utiquitin proteolysis system
76. E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis
77. p53-independent increase in E2F-1 expression enhances the cytotoxic effects of etoposide and of Adriamycin